3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
4
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
1
Interventions
Cyclophosphamide
641
Bevacizumab
552
Paclitaxel
534
Carboplatin
533
Cisplatin
480
pembrolizumab
456
Gemcitabine
422
Docetaxel
415
Rituximab
386
Radiotherapy
373
Dexamethasone
351
Doxorubicin
330
Nivolumab
308
Fluorouracil
286
Capecitabine
260
Etoposide
245
Prednisone
244
Oxaliplatin
242
Erlotinib Hydrochloride
242
Cytarabine
233
Lenalidomide
232
Trastuzumab
226
Pemetrexed
220
Vincristine
212
fludarabine phosphate
208
Leucovorin
208
Cetuximab
208
Filgrastim
204
Bortezomib
193
Methotrexate
183
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Has results
×
melflufen
×
Clear all
NCT02963493
2022-11-22
HORIZON
Oncopeptides AB
Phase 2
Completed
157 enrolled
26 charts
1 FDA